Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Inhaled Doses of Imatinib Inhalation Solution (AER-901) in Adult Healthy Volunteers

Next Previous
Trial Profile

A Randomised, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Inhaled Doses of Imatinib Inhalation Solution (AER-901) in Adult Healthy Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 12 Oct 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Imatinib (Primary) ; Imatinib
  • Indications Pulmonary arterial hypertension; Pulmonary hypertension
  • Focus Adverse reactions
  • Sponsors Aerami Therapeutics

Most Recent Events

  • 05 Oct 2023 According to an Aerami Therapeutics media release, extended pharmacokinetic findings from the completed Phase 1 clinical trial of AER-901 in healthy volunteers (NCT04903730) to support dose and dosing regimen selection for the planned uniPHied Phase 2 platform trial in PH-ILD and PAH will be presented at the upcoming CHEST 2023 conference
  • 13 Sep 2023 Results presented at the 33rd Annual Congress of the European Respiratory Society
  • 12 Sep 2023 According to an Aerami Therapeutics media release, results from this trial were presented at the 2023 European Respiratory Society (ERS) International Congress.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top